All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to BuyZacks Investment Research • 05/10/23
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer PatientsBusiness Wire • 05/09/23
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite ScientistsBusiness Wire • 05/02/23
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward CommercializationBusiness Wire • 04/24/23
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis TreatmentBusiness Wire • 04/10/23
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and NamodenosonBusiness Wire • 03/16/23
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use SettingBusiness Wire • 03/13/23
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for PlaceboBusiness Wire • 02/14/23
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been FiledBusiness Wire • 01/24/23
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private PlacementBusiness Wire • 01/11/23
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to FollowBusiness Wire • 01/10/23
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver CancerBusiness Wire • 12/28/22
Can-Fite's Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets' OsteoarthritisBusiness Wire • 12/08/22
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical UpdateBusiness Wire • 11/25/22
Can-Fite: Positive New Data from it's Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in BostonBusiness Wire • 11/02/22
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®Business Wire • 10/25/22
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming ConferenceBusiness Wire • 10/13/22
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of DermatologyBusiness Wire • 09/12/22
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical UpdateBusiness Wire • 08/25/22
Can-Fite's Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in RomaniaBusiness Wire • 08/23/22
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology CongressBusiness Wire • 08/22/22
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner VetbiolixBusiness Wire • 08/17/22